China's BeiGene said it has completed financing of more than CNY450 million ($75 million) from initial angel and strategic investors as well as new investors Hillhouse Capital and CITIC PE, joined by an unnamed "blue chip U.S. public investment fund" specializing in life sciences.
Alongside the launch of a next generation sequencing-based oncology assay, Silicon Valley Biosystems is also rolling out a new name to reflect its mission of providing practical genetic information to patients.
For William Strohl, the new head of Janssen's Biotechnology Center of Excellence, the future of drug R&D involves novel targets, "fit-for-purpose" antibodies and lots of collaborations.
When Flatiron Health emerged in 2012 with a mission to improve oncology care, its founder predicted it would either be "a great success or a horrible failure." Now the Big Data startup is reportedly on the cusp of taking a major step towards the better of these two outcomes, with Fortune writing Google's venture capital wing is leading a $100 million financing round.
GlaxoSmithKline is launching what it calls the Oncology Clinical and Translational Consortium, a collaborative scientific research network intended to advance drug discovery that will include 6 cancer centers around the world.
Indian officials fear the sale of the vaccine and oncology plants will limit the country's ability to supply affordable medicines to citizens.
When ex-Google ($GOOG) guys Nat Turner and Zach Weinberg discussed their oncology-focused startup Flatiron Health in August they were big on ambition but low on details.
A group of investigators at the prestigious Dana-Farber/Children's Hospital Cancer Center in Boston believe they may have identified the Achilles heel for a common malignant tumor found in pediatric oncology.
Personalized medicine has been the holy grail of diagnostics and biomarkers for some time, but at last, it seems like it is becoming a reality. Jan Groen, CEO at MDxHealth, spoke to FierceBiomarkers at BIO2012 about this growing field.
Cancer systems biology algorithms have led researchers to two genes that collaborate to cause an aggressive brain tumor. Researchers from Columbia University and oncology drug discovery company